Simplify Life with Omnipod® 5
See How It Works
Proactively helps to correct highs and protect from lows1-3
No daily insulin injections or tangled tubes
Shown to lower A1C1-3
Now with algorithm enhancements, including new lower 100mg/dL Target Glucose, designed for more time in range.4
Innovation at your fingertips
With Omnipod 5, the Pod and compatible CGM sensor are in continuous communication.The CGM sensor sends glucose values and trends to the Pod to help the system make automated insulin delivery decisions every 5 minutes, which helps keep you in range.1-3 And, you can control it all from your fingertips with the Omnipod 5 app on a compatible smartphone.†
†For a list of compatible smartphone devices, visit omnipod.com/compatibility
Omnipod 5 is available at your Local Pharmacy
Omnipod 5 is available exclusively through the pharmacy and has over 90% coverage,‡ which means you or your loved one can make the switch to Omnipod 5 from daily injections, a tubed pump, or even another Omnipod product at almost any time as your coverage and approvals allow. The best part—most Omnipod 5 users pay $30 or less per month!§
The #1 Prescribed Automated Insulin Delivery System*
*USA 2025, Data on File
The support you need to succeed
With Omnipod, you get more than just an insulin management system, you also get:
- Access to a 24/7 support team
- Training sessions and materials to get you started
- User guides, “how-to” videos, and resources to help along the way
- A community of Podders just like you, sharing tips and experiences for simplifying life with diabetes
When you get started on Omnipod, you’re no longer on your own managing your diabetes. With a team of dedicated support professionals and seemingly endless resources at your fingertips, we make it our mission to help you be successful.
Real stories of lives made simpler with Omnipod 5
Omnipod 5 for type 1 diabetes:
Meet Sponsored Podder® Garrett
Omnipod 5 for type 2 diabetes:
Meet Sponsored Podder® Milli
Have questions? Talk to an Omnipod Specialist today!
We have a team of Omnipod specialists ready to answer your questions. Complete the short form below and we will reach out as soon as we can.
Risk Statement
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod® 5 System is intended for single patient, home use and requires a prescription. The Omnipod® 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, Kirsty®, and Admelog®.
Warning: The Omnipod 5 algorithm should NOT be used by anyone under the age of 2 years old. The Omnipod 5 algorithm should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.
Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.
1. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Average time with low blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 2.9% vs. 1.3%; 2.2% vs. 1.8%. Mean HbA1c in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 7.16% vs 6.78%, P<0.0001; 7.67% vs 6.99%, P<0.0001, respectively. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Study funded by Insulet.
2. Sherr JL, et al. Diabetes Care (2022). Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 39.4% vs. 29.5%. Average time with low blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 3.43% vs. 2.46%. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05. Study funded by Insulet.
3. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL as measured by CGM: ST = 54%, 3-mo Omnipod 5 = 34%, P<0.001. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-mo Omnipod 5 = 0.2%. Mean HbA1c: ST vs. 13-week Omnipod 5: 8.2% vs. 7.4%, P<0.001. Mean time in range (70-180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001.
4. In a simulated analysis, the 100 mg/dL Target Glucose (TG) setting demonstrated superior Time in Range (70-180 mg/dL) compared with results at the 110-150 mg/dL TG settings in a real-world population of people with T1D using Omnipod 5. Statistically significant differences in mean TIR were observed for Target 100 mg/dL vs. 110, 120, 130, 140, and 150 mg/dL, with differences of 2.5%, 4.8%, 9.8%, 15.3%, and 20.8%, respectively. Data on File. RF-012026-00057.
†For a list of compatible smartphone devices, visit omnipod.com/compatibility
‡Reflects coverage for Omnipod 5 DexG7G6 Pods. Source: Insulet Data as of 2025. RF-012026-00067
§Majority defined as at least 50% of patient co-pays $30 or less per month. Among All Paid Omnipod 5 DexG7G6 and Libre2Plus Pods Commercial and Medicare Claims from January 2025 to December 2025. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library. RF-012026-00067.
*USA 2025, Data on File